Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma-Reference-Cited by-同舟云学术

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

Published:2014-10-18 Issue:21 Volume:5 Page:10206-10221
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Spagnolo Francesco¹,Ghiorzo Paola²³,Queirolo Paola⁴

Affiliation:

1. Department of Plastic and Reconstructive Surgery - IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale per la Ricerca sul Cancro - Genova, Italy

2. Genetics of rare cancers, Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genova, Italy

3. IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

4. Department of Medical Oncology - IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale per la Ricerca sul Cancro - Genova, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AMBRA1 levels predict resistance to MAPK inhibitors in melanoma;Proceedings of the National Academy of Sciences;2024-06-13

2. Alantolactone enhances the sensitivity of melanoma to MAPK pathway inhibitors by targeting inhibition of STAT3 activation and down-regulating stem cell markers;Cancer Cell International;2024-05-31

3. ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework;npj Precision Oncology;2024-03-14

4. Cold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro;Journal of Biophotonics;2023-12-19

5. Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma;Current Medicinal Chemistry;2023-10-19